Analyst Price Targets — MCRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 7, 2024 5:10 am | Keay Nakae | Chardan Capital | $1.25 | $0.85 | TheFly | Seres Therapeutics price target lowered to $1.25 from $6 at Chardan |
Latest News for MCRB
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune…
Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MCRB.
U.S. House Trading
No House trades found for MCRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.